1. Awareness of physicians and pharmacists of aldosterone antagonists in heart failure and myocardial infarction in Jordan
- Author
-
Fadia Mayyas, Karem H. Alzoubi, and Khalid E. Ibrahim
- Subjects
Clinical audit ,mesh:Heart Failure ,Myocardial Infarction ,Pharmaceutical Science ,lcsh:RS1-441 ,Pharmacy ,030204 cardiovascular system & hematology ,Pharmacists ,chemistry.chemical_compound ,0302 clinical medicine ,Surveys and Questionnaires ,mesh:Mineralocorticoid Receptor Antagonists ,mesh:Practice ,030212 general & internal medicine ,Myocardial infarction ,Original Research ,Mineralocorticoid Receptor Antagonists ,Response rate (survey) ,Practice ,Aldosterone ,Health Knowledge ,mesh:Attitudes ,mesh:Myocardial Infarction ,mesh:Jordan ,medicine.medical_specialty ,mesh:Health Knowledge ,mesh:Physicians ,lcsh:Pharmacy and materia medica ,03 medical and health sciences ,Physicians ,medicine ,mesh:Pharmacists ,Medical prescription ,Intensive care medicine ,Health Knowledge Attitudes Practice ,Heart Failure ,Clinical Audit ,Jordan ,business.industry ,lcsh:RM1-950 ,medicine.disease ,Clinical pharmacy ,mesh:Clinical Audit ,lcsh:Therapeutics. Pharmacology ,chemistry ,Heart failure ,Attitudes ,Emergency medicine ,mesh:Surveys and Questionnaires ,Spironolactone ,business - Abstract
Objective: to evaluate physicians and clinical pharmacists’ awareness and practices regarding use of aldosterone antagonists in heart failure (HF) and post-myocardial infarction (MI). Methods: First, we reviewed the prescription of aldosterone antagonists among 408 patients presenting to the cardiology clinic at a major hospital in Jordan. Second, physicians and pharmacists working in cardiovascular departments completed a questionnaire related to use of aldosterone antagonists in HF and post-MI. Results: Thirty patients (7.59%) were eligible for aldosterone antagonist; only 4 received them at discharge (13.3%). The survey was completed by 153 professionals (response rate 76.12%). About 72.1% of participants were aware of studies regarding use of aldosterone antagonists post-MI and in HF. Moreover, 10.45%/53.6% of participants strongly agreed/agreed that these agents are useful in normotensive post-MI and HF patients. Spironolactone was the most prescribed drug by 92.1% of participants. About 41.8% of participants reported use of spironolactone in post-MI and HF. With respect to guidelines, only 39.2% of participants agreed that adding spironolactone to standard therapy in HF is recommended, and 48.3% agreed on adding it directly post-MI. Clinical pharmacists and cardiologists were generally more aware of guidelines than pharmacists, cardiac surgeons and residents/fellows. Conclusions: there is an under-use of aldosterone antagonists in HF and post-MI patients, and a lack of detailed awareness of current guidelines among health care providers. Dissemination of evidence-based guidelines and usage protocols may improve management of post-MI and HF.
- Published
- 2017